
    
      BIOFLOW-VIII is a national, prospective, non-randomized, multi-center, open-label registry to
      confirm both, the acute performance as well as the mid- and long-term safety and clinical
      performance of the Orsiro Mission stent in an all-comers patient population within daily
      clinical practice.

      A total of 868 subjects will be enrolled at approximately 50 study sites in France. Clinical
      follow-ups will take place at 6, 12, 36 and 60 months post index-procedure. Follow-ups can be
      conducted by telephone.

      A subgroup analysis will evaluate the outcomes for patients treated ambulatory with same day
      discharge.
    
  